title: CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis.
abstract: BACKGROUND
  CHEK2 encodes for a G2 checkpoint kinase which plays a critical role in DNA repair. Its mutation confers an increased risk of breast cancer. It has also been suggested to increase risks of prostate cancer, but its involvement with this type of cancer has not been confirmed.
  
  
  METHODS
  We performed a systematic review and meta-analysis to clarify the association between CHEK2 1100delC, IVS2+1G>A, I157T mutation and risk of Prostate Cancer. A comprehensive, computerized literature search of PubMed until December 27, 2014 was carried out. Eligible studies were included according to specific inclusion criteria. Pooled hazard ratio was estimated using the fixed effects model or random effects model according to heterogeneity between studies.
  
  
  RESULTS
  Eight eligible studies were included in the analysis, all were retrospective studies. The overall meta-analysis demonstrated that the CHEK2 1100delC mutation (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00) and I157T missense mutation (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00) was associated with higher risk of Prostate Cancer, and CHEK2 1100delC mutation is irrelevant to familial aggregation phenomenon of prostate cancer (OR 1.59; 95% confidence interval: 0.79-3.20; P = 0.20). The IVS2+1G>A mutation is also irrelevant to Prostate Cancer (OR = 1.59, 95% CI = 0.93-2.71, P = 0.09). None of the single studies materially altered the original results and no evidence of publication bias was found.
  
  
  CONCLUSIONS
  CHEK2 1100delC mutation and I157T missense mutation in males indicates higher risk of Prostate Cancer, but there's no evidence to prove the CHEK2 1100delC mutation was associated with Familial prostate cancer.
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Center Shanghai 20032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 20032, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Center Shanghai 20032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 20032, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Dai
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Center Shanghai 20032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 20032, China.
authors.forename: Dingwei
authors.initials: D
authors.lastname: Ye
keywords: CHEK2 mutation; Prostate cancer; risk of prostate cancer